{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:58:41Z","timestamp":1791298721352,"version":"4.1.0"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,2,15]]},"DOI":"10.2169\/internalmedicine.2779-19","type":"journal-article","created":{"date-parts":[[2019,10,6]],"date-time":"2019-10-06T22:03:17Z","timestamp":1570399397000},"page":"563-567","source":"Crossref","is-referenced-by-count":6,"title":["Eribulin-induced Interstitial Pneumonia: A Case Series and Retrospective Cohort Study"],"prefix":"10.2169","volume":"59","author":[{"given":"Manabu","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kanemura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tomishima","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, St. Luke's International Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohide","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Thoracic Center, St. Luke's International Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Toru M, Shunji N, Hirofumi M, et al. Eribulin mesylate in patients with refractory cancers: a Phase I study. Invest New Drugs 30: 1926-1933, 2012."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Aogi K, Iwata H, Masuda N, et al. A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol 23: 1441-1448, 2012.","DOI":"10.1093\/annonc\/mdr444"},{"key":"3","unstructured":"3. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 377: 914-923, 2011."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol 28: 3922-3928, 2010.","DOI":"10.1200\/JCO.2009.25.8467"},{"key":"5","unstructured":"5. The package insert of eribulin [Internet]. [cited 2019 Jan 31]. Available from: http:\/\/www.info.pmda.go.jp\/go\/pack\/4291420A1022_1_07\/ (in Japanese)."},{"key":"6","unstructured":"6. Post-marketing surveillance for the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer (Study HAL01S) [Internet]. [cited 2019 Jan 31]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01463891"},{"key":"7","unstructured":"7. Nakamura K, Kato M, Miyashita Y, et al. Development of interstitial pneumonia during treatment with eribulin: a case report. BMC Res Notes 10: 557, 2017."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ishida H, Honma T, Ishida K, et al. Pneumonia induced by eribulin mesylate in a patient with recurrent breast cancer. Int Canc Conf J 2: 135-138, 2013.","DOI":"10.1007\/s13691-012-0076-4"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Tamura M, Saraya T, Fujiwara M, et al. High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases. Oncologist 18: 454-459, 2013.","DOI":"10.1634\/theoncologist.2012-0248"},{"key":"10","unstructured":"10. Kondo A. Drug-induced pneumonitis. Kekkaku (Tuberculosis) 74: 33-41, 1999 (in Japanese, Abstract in English)."},{"key":"11","unstructured":"11. Foucher P, Camus P. The drug-induced respiratory disease website. Pneumotox [Internet]. [cited 2019 Jan 31]. Available from: http:\/\/www.pneumotox.com"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Camus P, Fanton A, Bonniaud P, et al. Interstitial lung disease induced by drugs and radiation. Respiration 71: 301-326, 2004.","DOI":"10.1159\/000079633"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Limper AH. Chemotherapy-induced lung disease. Clin Chest Med 25: 53-64, 2004.","DOI":"10.1016\/S0272-5231(03)00123-0"},{"key":"14","unstructured":"14. Fitzmaurice C, Akinyemiju TF, et al.; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol 3: 524-548, 2017."}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/4\/59_2779-19\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T03:39:34Z","timestamp":1581737974000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/4\/59_2779-19\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,15]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.2779-19","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,15]]}}}